Childhood Arthritis and Rheumatology Research for Dreams Come True Remission

A special issue of Children (ISSN 2227-9067).

Deadline for manuscript submissions: 10 January 2025 | Viewed by 1819

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan
Interests: allergy; immunology; juvenile dermatomyositis; Kawasaki disease; pediatric rheumatology; rheumatology

E-Mail Website
Guest Editor
Professor Emeritus, Department of Pediatrics, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan
Interests: dreams come true remission; juvenile dermatomyositis; juvenile idiopathic arthritis; pediatric rheumatology; Sjögren’s syndrome; systemic lupus erythematosus

Special Issue Information

Dear Colleagues,

Pediatric rheumatic diseases (PRDs) are chronic inflammatory systemic diseases caused by autoimmune responses which develop in childhood and are represented by juvenile idiopathic arthritis, systemic lupus erythematosus, dermatomyositis, Sjögren’s syndrome, and autoinflammatory diseases.

Recent advances in the treatment of PRDs have been remarkable and will continue to develop. In the past, the prognosis of PRDs in children was poor, and disease- and treatment-related complications and sequelae were major problems. Nowadays, various biologics and molecular-targeted drugs are available, and remission of PRDs is possible in many children.

On the other hand, the treatment of PRDs aimed at attaining “dreams come true” remission is expected in the future. The concept of “dreams come true” remission, first introduced by Prof. Takei, is a kind of remission that enables children with PRDs to realize their future dreams without being disrupted by their diseases. Naturally, this cannot be achieved with conventional treatment aimed at clinical, structural, and functional remission. For a treatment to achieve “dreams come true” remission, it must first encourage children to make their own dreams.

This Special Issue invites the latest reviews and original articles in pediatric rheumatology for the realization of future “dreams come true” remission.

Dr. Hiroyuki Wakiguchi
Prof. Dr. Syuji Takei
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pediatric rheumatic diseases
  • juvenile idiopathic arthritis
  • systemic lupus erythematosus
  • dermatomyositis
  • Sjögren’s syndrome
  • autoinflammatory diseases
  • biological disease-modifying antirheumatic drugs
  • targeted synthetic disease-modifying antirheumatic drugs
  • prognosis
  • “Dreams come true” remission

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

3 pages, 159 KiB  
Editorial
Childhood Arthritis and Rheumatology Research for Dreams Come True Remission
by Syuji Takei
Children 2022, 9(3), 324; https://doi.org/10.3390/children9030324 - 1 Mar 2022
Cited by 1 | Viewed by 1671
Abstract
In recent years, newly developed therapeutic agents have brought clinical, structural, and functional remission to many pediatric patients with rheumatic diseases that were refractory to conventional therapy. However, achieving these remissions alone is insufficient as a treatment goal, especially for adolescent patients, because [...] Read more.
In recent years, newly developed therapeutic agents have brought clinical, structural, and functional remission to many pediatric patients with rheumatic diseases that were refractory to conventional therapy. However, achieving these remissions alone is insufficient as a treatment goal, especially for adolescent patients, because advanced therapies have not always encouraged their psychosocial stability and mental maturity. Consequently, various problems have arisen during the puberty and transition period from pediatrics to adult medical care. “Dreams come true remission” is a state of remission that allows patients to have clear dreams for the future in childhood and to increase the potential that their dreams will be realized in adulthood. This new treatment goal may empower children with chronic diseases such as PRDs to overcome the problems occurred during puberty and transition period. Full article
Back to TopTop